Assessment of Patient Experiences with Respimat® in Everyday Clinical Practice

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is a progressive disease requiring maintenance therapy. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report, bronchodilation with long-acting muscarinic antagonists (LAMAs) and long-acting b 2-agonists (LABAs), administered via inhalers, is currently the mainstay of COPD treatment. Combined LAMA/LABA therapies have been shown to improve patient health status, lung function and breathlessness. Here, we wanted to report patient satisfaction with the Respimat Ò Soft Mist TM inhaler (SMI). Methods: This was a pooled analysis of SPIRIT Ò (NCT02675517) and OTIVACTO Ò (NCT02719639), two open-label, single-arm, non-interventional studies of physical function in patients with COPD. Patients were treated with tiotropium/olodaterol 5/5 lg for approximately 6 weeks via the SMI. SPIRIT was conducted in Germany; OTIVACTO was conducted in nine European countries. The primary endpoints have been reported previously. Here, we assess patient satisfaction with inhalation and handling, and patient adherence to treatment with the tiotropium/olodaterol SMI in patients with COPD. These were assessed through selfreported questionnaires and physician general assessments. Results: Baseline data were collected from 9180 patients from the SPIRIT and OTIVACTO studies. The majority of patients were GOLD group A (25.59%) or B (46.12%). After 6 weeks of treatment with tiotropium/olodaterol, 85.78% of patients were 'satisfied' or 'very satisfied' with inhaling from the device, and 84.33% of patients were 'satisfied' or 'very satisfied' with the handling of the inhaler. Treating physicians reported patient adherence as 'high' during the study, with 98.57% of patients regularly using the tiotropium/olodaterol SMI. Furthermore, 95.45% of patients expressed a willingness to continue using the tiotropium/olodaterol SMI at the end of the observation period. Conclusion: In this study, over 9000 patients reported satisfaction with respect to inhalation Digital Features To view digital features for this article go to

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS

“…The EVELUT study builds upon this evidence base by providing data from a longer follow-up period (~ 12 weeks). High levels of patient satisfaction with the inhaler device and with treatment overall were reported in both arms after 12 weeks, consistent with previous non-interventional studies reporting patient-reported outcomes for Tio/Olo [ 12 , 13 , 15 , 16 ]. Patients using ≥ 2 products for TT had the highest levels of satisfaction, suggesting that, contrary to previous studies [ 17 , 18 ], patients may not necessarily prefer to use a single device and may prefer to use devices that they are familiar with to manage their COPD.…”

Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study

“…30,52 Studies in patients with COPD have also previously shown that the Respimat ® device is easy to use, reliable and durable, with high reported levels of satisfaction with the device. [52][53][54][55][56] In the current study, satisfaction with device handling was slightly higher for younger patients, but still had good results in older patients (80% of those ≤65 years were satisfied or very satisfied, versus 75% for those >65 years).…”

Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines

“…They reported that 85% and 84% of patients, respectively, were content with using and handling the inhaler. Interestingly, over 95% of people continued using the inhaler after the study ended ( 79 ).…”